Top

Published in:

01-07-2008

Anti-annexin II Antibodies in Systemic Autoimmune Diseases and Antiphospholipid Syndrome

Authors: V. Salle, J. C. Mazière, A. Smail, R. Cévallos, C. Mazière, V. Fuentes, B. Tramier, R. Makdassi, G. Choukroun, O. Vittecoq, V. Goëb, J. P. Ducroix

Published in: Journal of Clinical Immunology | Issue 4/2008

Abstract

Objectives

The objective of this study were (1) to evaluate the prevalence of anti-annexin II antibodies in patients with various autoimmune diseases and antiphospholipid syndrome and (2) to correlate anti-annexin II antibodies with anti-phospholipid antibodies.

Materials and Methods

Anti-annexin II antibodies and anti-phospholipid were detected, using an enzyme-linked immunosorbent assay, in the serum of patients with primary antiphospholipid syndrome (n = 16), systemic lupus erythematosus (n = 53), primary Sjögren syndrome (n = 71), systemic sclerosis (n = 17), systemic vasculitis (n = 18), and rheumatoid arthritis (n = 119). Healthy blood donors (n = 99) were used as controls.

Results

Anti-annexin II antibodies were significantly more prevalent in patients with connective tissue diseases (8.5%), especially antiphospholipid syndrome (14.8%) and rheumatoid arthritis (10%), than in controls (2%). An inverse correlation was observed between anti-annexin II antibodies and antiphospholipid antibodies.

Conclusion

Annexin II can be recognized by antibodies in serum from patients with systemic autoimmune disorders. Further studies are required to determine the clinical significance of anti-annexin II antibodies in rheumatoid arthritis and to determine their diagnostic value in discriminating clinical subgroups of patients with antiphospholipid syndrome.

Takeuchi R, Atsumi T, Ieko M, Amasaki Y, Ichikawa K, Koike T. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome. Br J Haematol 2002;119:781–8.PubMedCrossRef

Kolev K, Gombas J, Varadi B, Skopal J, Mede K, Pitlik E, et al. Immunoglobulin G from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin. Thromb Haemost 2002;87:502–8.PubMed

Espinosa G, Cervera R, Font J, Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms. Autoimmun Rev 2003;2:86–93.PubMedCrossRef

Patterson AM, Ford I, Graham A, Booth NA, Greaves M. The influence of anti-endothelial/antiphospholipid antibodies on fibrin formation and lysis on endothelial cells. Br J Haematol 2006;133:323–30.PubMedCrossRef

Jurado M, Paramo JA, Gutierrez-Pimentel M, Rocha E. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost 1992;68:516–20.PubMed

Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752–63.PubMedCrossRef

Siever DA, Erickson HP. Extracellular annexin II. Int J Biochem Cell Biol 1997;29:1219–23.PubMedCrossRef

Kristoffersen EK, Matre R. Surface annexin II on placental membranes of the fetomaternal interface. Am J Reprod Immunol 1996;36:141–9.PubMed

Hajjar KA, Krishnan S. Annexin II: a mediator of the plasmin/plasminogen activator system. Trends Cardiovasc Med 1999;9:128–38.PubMedCrossRef

10.

Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. J Biol Chem 1994;269:21191–7.PubMed

11.

Ma K, Simantov R, Zhang JC, Silverstein R, Hajjar KA, McCrae KR. High affinity binding of β2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000;275:15541–8.PubMedCrossRef

12.

Zhang J, McCrae KR. Annexin II mediates endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood 2005;105:1964–9.PubMedCrossRef

13.

Cesarman-Maus G, Rios-Luna NP, Deora AB, Huang B, Villa R, Cravioto MdC, et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006;107:4375–82.PubMedCrossRef

14.

Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.PubMedCrossRef

15.

Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.PubMedCrossRef

16.

Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999;42:1309–11.PubMedCrossRef

17.

Harris EN, Pierangeli SS. ’Equivocal’ antiphospholipid syndrome. J Autoimmun 2000;15:81–5.PubMedCrossRef

18.

Masi AT, Rodnan GP, Medsger TA Jr, Altman RD, D’Angelo WA, Fries JF, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581–90.CrossRef

19.

LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573–6.PubMed

20.

Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990;33:1101–7.PubMedCrossRef

21.

Lightfoot RW, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33:1088–93.PubMedCrossRef

22.

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 2002;61:554–8.PubMedCrossRef

23.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.PubMedCrossRef

24.

Perez-Vazquez ME, Villa AR, Drenkard C, Cabiedes J, Alarcon-Segovia D. Influence of disease duration, continued follow-up and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus. J Rheumatol 1993;20:437–42.PubMed

25.

Vittecoq O, Jouen-Beades F, Krzanowska K, Bichon-Tauvel I, Menard JF, Daragon A, et al. Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis. Rheumatology 2000;39:481–9.PubMedCrossRef

26.

Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004;34:501–37.PubMedCrossRef

27.

Goulding NJ, Dixey J, Morand EF, Dodds RA, Wilkinson LS, Pitsillides AA, et al. Differential distribution of annexins-I, -II, -IV, and -VI in synovium. Ann Rheum Dis 1995;54:841–5.PubMedCrossRef

28.

Justen HP, Grunewald E, Totzke G, Gouni-Berthold I, Sachinidis A, Wessinghage D, et al. Differential gene expression in synovium of rheumatoid arthritis and osteoarthritis. Mol Cell Biol Res Commun 2000;3:165–72.PubMedCrossRef

29.

Dubois T, Bisagni-Faure A, Coste J, Mavoungou E, Menkes CJ, Russo-Marie F, et al. High levels of antibodies to annexins V and VI in patients with rheumatoid arthritis. J Rheumatol 1995;22:1230–4.PubMed

30.

Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004;113:38–48.PubMed

Title: Anti-annexin II Antibodies in Systemic Autoimmune Diseases and Antiphospholipid Syndrome
Authors: V. Salle
J. C. Mazière
A. Smail
R. Cévallos
C. Mazière
V. Fuentes
B. Tramier
R. Makdassi
G. Choukroun
O. Vittecoq
V. Goëb
J. P. Ducroix
Publication date: 01-07-2008
Publisher: Springer US
Published in: Journal of Clinical Immunology / Issue 4/2008
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-008-9188-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Anti-annexin II Antibodies in Systemic Autoimmune Diseases and Antiphospholipid Syndrome

Abstract

Objectives

Materials and Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objectives

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2008

Lack of Association of the Vascular Endothelial Growth Factor Gene Polymorphisms with Kawasaki Disease in Taiwanese Children

Association of Four-locus Gene Interaction with Aspirin-intolerant Asthma in Korean Asthmatics

Cytokine Secretion in Long-standing Diabetes Mellitus Type 1 and 2: Associations with Low-grade Systemic Inflammation

Primary Immunodeficiency Disorders: Survey of Pediatricians in Kuwait

Regulatory Role of Promoter and 3′ UTR Variants of Vitamin D Receptor Gene on Cytokine Response in Pulmonary Tuberculosis

Polymorphisms of KIRs Gene and HLA-C Alleles in Patients with Ankylosing Spondylitis: Possible Association with Susceptibility to the Disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page